Literature DB >> 6945143

The treatment of osteosarcoma of the extremities: twenty year's experience at the Istituto Ortopedico Rizzoli.

M Campanacci, G Bacci, F Bertoni, P Picci, A Minutillo, C Franceschi.   

Abstract

Twenty year's (1959-1979) experience in the treatment of osteosarcoma at the Bone Tumor Center of the Istituto Ortopedico Rizzoli is presented. During this period 433 cases were recorded, but only 266 were considered. All the patients underwent surgery but after 1970 whole-lung irradiation (1971), immunotherapy (1971), and chemotherapy (1972 onward) were added as adjuvant therapies on a nonrandomized basis. In the group treated with surgery alone the prognosis was very poor: 10% survived nine years or more after the diagnosis, an average disease-free interval of 7.7 months and an average survival time of 13 months. Monolateral whole-lung irradiation had negative results and was abandoned after six cases. Adjuvant immunotherapy with irradiated autologous tumor cells gave moderately positive results in 16 patients, but only by delaying the appearance of first metastases, therefore increasing the time of survival. Adjuvant chemotherapy was performed with three different protocols: one protocol with ADM only and two protocols using VCR + MTX (at medium dose) + ADM, administered according to two different schedules. Superimposable results were obtained with these three regimens. With equal follow-up, the percentage of continuously disease-free patients treated with adjuvant chemotherapy was significantly higher than that of patients treated with surgery alone (P less than 0.001). The patients in the chemotherapy group who had relapses showed a prolonged time (mean = 12.3 months) to the onset of the first metastasis. Adjuvant chemotherapy caused virtually no morbidity and no deaths. Reference is made to the advantages of a large and homogeneous caseload deriving from a single institution to avoid preselection bias and evaluate the effectiveness of new therapeutic approaches when patient randomization has not been employed.

Entities:  

Mesh:

Year:  1981        PMID: 6945143     DOI: 10.1002/1097-0142(19811001)48:7<1569::aid-cncr2820480717>3.0.co;2-x

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  19 in total

1.  [New morphologic findings in malignant bone tumors].

Authors:  G Delling
Journal:  Langenbecks Arch Chir       Date:  1987

Review 2.  Systematic review of high-dose and standard-dose chemotherapies in the treatment of primary well-differentiated osteosarcoma.

Authors:  Fu-You Zhang; Wei Tang; Zhi-Zhong Zhang; Jian-Cheng Huang; Shu-Xiang Zhang; Xue-Chun Zhao
Journal:  Tumour Biol       Date:  2014-07-23

3.  Prevalence of Metastasis at Diagnosis of Osteosarcoma: An International Comparison.

Authors:  Tracy A Marko; Brandon J Diessner; Logan G Spector
Journal:  Pediatr Blood Cancer       Date:  2016-02-29       Impact factor: 3.167

4.  Isolation perfusion of the lower limb with platinum.

Authors:  M Vaglini; F Belli; M Santinami
Journal:  World J Surg       Date:  1988-06       Impact factor: 3.352

5.  Inhibition of tumors cell growth in osteosarcoma-bearing SD rats through a combination of conventional and metronomic scheduling of neoadjuvant chemotherapy.

Authors:  Xiao-zhong Zhu; Hong-mei Yin; Jiong Mei
Journal:  Acta Pharmacol Sin       Date:  2010-08       Impact factor: 6.150

6.  The efficacy of high-dose versus moderate-dose chemotherapy in treating osteosarcoma: a systematic review and meta-analysis.

Authors:  Wei-Guang Wang; Chao Wan; Guang-Jun Liao
Journal:  Int J Clin Exp Med       Date:  2015-09-15

7.  Intracortical osteosarcoma: rare entity or early manifestation of classical osteosarcoma?

Authors:  P Picci; F Gherlinzoni; A Guerra
Journal:  Skeletal Radiol       Date:  1983       Impact factor: 2.199

8.  Telomerase activity in skeletal sarcomas.

Authors:  G Aue; B Muralidhar; H S Schwartz; M G Butler
Journal:  Ann Surg Oncol       Date:  1998 Oct-Nov       Impact factor: 5.344

9.  Therapeutic efficacy of soluble receptor activator of nuclear factor-kappa B-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma.

Authors:  François Lamoureux; Gaëlle Picarda; Julie Rousseau; Clothilde Gourden; Séverine Battaglia; Céline Charrier; Bruno Pitard; Dominique Heymann; Françoise Rédini
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

Review 10.  Current status and perspectives regarding the treatment of osteo-sarcoma: chemotherapy.

Authors:  Akio Sakamoto; Yukihide Iwamoto
Journal:  Rev Recent Clin Trials       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.